A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE)

Rationale: This is the first multicenter randomized controlled trial to evaluate the effectiveness and safety of Zephyr Endobronchial Valve (EBV) in patients with little to no collateral ventilation out to 12 months. Objectives: To evaluate the effectiveness and safety of Zephyr EBV in heterogeneous emphysema with little to no collateral ventilation in the treated lobe. Methods: Subjects were enrolled with a 2:1 randomization (EBV/standard of care [SoC]) at 24 sites. Primary outcome at 12 months was the &Dgr;EBV‐SoC of subjects with a post‐bronchodilator FEV1 improvement from baseline of greater than or equal to 15%. Secondary endpoints included absolute changes in post‐bronchodilator FEV1, 6‐minute‐walk distance, and St. George's Respiratory Questionnaire scores. Measurements and Main Results: A total of 190 subjects (128 EBV and 62 SoC) were randomized. At 12 months, 47.7% EBV and 16.8% SoC subjects had a &Dgr;FEV1 greater than or equal to 15% (P < 0.001). &Dgr;EBV‐SoC at 12 months was statistically and clinically significant: for FEV1, 0.106 L (P < 0.001); 6‐minute‐walk distance, +39.31 m (P = 0.002); and St. George's Respiratory Questionnaire, −7.05 points (P = 0.004). Significant &Dgr;EBV‐SoC were also observed in hyperinflation (residual volume, −522 ml; P < 0.001), modified Medical Research Council Dyspnea Scale (−0.8 points; P < 0.001), and the BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) index (−1.2 points). Pneumothorax was the most common serious adverse event in the treatment period (procedure to 45 d), in 34/128 (26.6%) of EBV subjects. Four deaths occurred in the EBV group during this phase, and one each in the EBV and SoC groups between 46 days and 12 months. Conclusions: Zephyr EBV provides clinically meaningful benefits in lung function, exercise tolerance, dyspnea, and quality of life out to at least 12 months, with an acceptable safety profile in patients with little or no collateral ventilation in the target lobe. Clinical trial registered with www.clinicaltrials.gov (NCT 01796392).

[1]  G. Hillerdal,et al.  A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM) , 2017, American journal of respiratory and critical care medicine.

[2]  F. Herth,et al.  Endobronchial Valves for Endoscopic Lung Volume Reduction: Best Practice Recommendations from Expert Panel on Endoscopic Lung Volume Reduction , 2016, Respiration.

[3]  F. Herth,et al.  Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study. , 2016, American journal of respiratory and critical care medicine.

[4]  E. V. van Rikxoort,et al.  Predicting Lung Volume Reduction after Endobronchial Valve Therapy Is Maximized Using a Combination of Diagnostic Tools , 2016, Respiration.

[5]  G. Michaud,et al.  Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema: The RENEW Randomized Clinical Trial. , 2016, JAMA.

[6]  F. Herth,et al.  Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. , 2016, The Lancet. Respiratory medicine.

[7]  C. Marquette,et al.  Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial. , 2016, JAMA.

[8]  E. V. van Rikxoort,et al.  Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. , 2015, The New England journal of medicine.

[9]  D. Hansell,et al.  Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial , 2015, The Lancet.

[10]  G. Washko,et al.  A randomised trial of lung sealant versus medical therapy for advanced emphysema , 2015, European Respiratory Journal.

[11]  Thierry Troosters,et al.  An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease , 2014, European Respiratory Journal.

[12]  Matthew S. Brown,et al.  Diagnostic performance comparison of the Chartis System and high‐resolution computerized tomography fissure analysis for planning endoscopic lung volume reduction , 2014, Respirology.

[13]  G. Criner,et al.  Pneumothorax following Endobronchial Valve Therapy and Its Impact on Clinical Outcomes in Severe Emphysema , 2014, Respiration.

[14]  G. Criner,et al.  Expert Statement: Pneumothorax Associated with Endoscopic Valve Therapy for Emphysema - Potential Mechanisms, Treatment Algorithm, and Case Examples , 2014, Respiration.

[15]  G. Criner,et al.  Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy , 2013, European Respiratory Journal.

[16]  T. Gislason,et al.  The impact of COPD on health status: findings from the BOLD study , 2013, European Respiratory Journal.

[17]  A. Holland,et al.  The return of the minimum clinically important difference for 6-minute-walk distance in chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[18]  F. Herth,et al.  Radiological and clinical outcomes of using Chartis™ to plan endobronchial valve treatment , 2012, European Respiratory Journal.

[19]  M. Noppen,et al.  Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort , 2012, European Respiratory Journal.

[20]  F. Martinez,et al.  The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery. , 2011, American journal of respiratory and critical care medicine.

[21]  R. Maxfield,et al.  Lung volume reduction surgery using the NETT selection criteria. , 2011, The Annals of thoracic surgery.

[22]  G. McLennan,et al.  A randomized study of endobronchial valves for advanced emphysema. , 2010, The New England journal of medicine.

[23]  B. Make,et al.  The minimal important difference of exercise tests in severe COPD , 2010, European Respiratory Journal.

[24]  M. Krasna,et al.  Lung volume reduction surgery: technique, operative mortality, and morbidity. , 2008, Proceedings of the American Thoracic Society.

[25]  G. Criner,et al.  National Emphysema Treatment Trial: the major outcomes of lung volume reduction surgery in severe emphysema. , 2008, Proceedings of the American Thoracic Society.

[26]  G. Washko,et al.  The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. , 2008, American journal of respiratory and critical care medicine.

[27]  B. Celli,et al.  The 6-min walking distance: long-term follow up in patients with COPD , 2007, European Respiratory Journal.

[28]  D. Wood,et al.  Patient and surgical factors influencing air leak after lung volume reduction surgery: lessons learned from the National Emphysema Treatment Trial. , 2006, The Annals of thoracic surgery.

[29]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[30]  R. L. Berger,et al.  Lung volume reduction surgery vs medical treatment: for patients with advanced emphysema. , 2005, Chest.

[31]  C. Goldsmith,et al.  Lung Volume Reduction Surgery vs Medical Treatment , 2005 .

[32]  J. Donohue.  Minimal Clinically Important Differences in COPD Lung Function , 2005, COPD.

[33]  J. Orens,et al.  A review of lung transplant donor acceptability criteria. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[34]  Steven Piantadosi,et al.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. , 2003, The New England journal of medicine.

[35]  D. Hansell,et al.  Effect of lung-volume-reduction surgery in patients with severe emphysema. , 2000, The New England journal of medicine.

[36]  R. Rogers,et al.  Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema. , 1996, The New England journal of medicine.

[37]  Y. Hochberg.  A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[38]  R. Firth.  Function , 1955, Yearbook of Anthropology.

[39]  James T.C. Li,et al.  Burden of chronic obstructive pulmonary disease: healthcare costs and beyond. , 2015, Allergy and asthma proceedings.

[40]  D. R. Jones.  Predictors of operative mortality and cardiopulmonary morbidity in the National Emphysema Treatment Trial , 2007 .

[41]  E. Hoffman,et al.  Predictors of operative mortality and cardiopulmonary morbidity in the National Emphysema Treatment Trial. , 2006, The Journal of thoracic and cardiovascular surgery.

[42]  G. Patterson,et al.  Chronic obstructive pulmonary disease • 10: Bullectomy, lung volume reduction surgery, and transplantation for patients with chronic obstructive pulmonary disease , 2003, Thorax.

[43]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.